FDA panel votes against approval of Sarepta Therapeutics drug

A Food and Drug Administration advisory panel voted against approval for Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen sending the stock price plummeting $3.88 to $11.07.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.